KR950000164A - Pseudomonas aeruginosa infectious agent and its manufacturing method - Google Patents

Pseudomonas aeruginosa infectious agent and its manufacturing method Download PDF

Info

Publication number
KR950000164A
KR950000164A KR1019930010281A KR930010281A KR950000164A KR 950000164 A KR950000164 A KR 950000164A KR 1019930010281 A KR1019930010281 A KR 1019930010281A KR 930010281 A KR930010281 A KR 930010281A KR 950000164 A KR950000164 A KR 950000164A
Authority
KR
South Korea
Prior art keywords
pseudomonas aeruginosa
cfcpa
kccm
agent
treating
Prior art date
Application number
KR1019930010281A
Other languages
Korean (ko)
Other versions
KR970001710B1 (en
Inventor
김현수
박완제
문우상
유왕돈
노갑수
이남중
김영지
조양제
Original Assignee
이종기
제일제당 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1019930010281A priority Critical patent/KR970001710B1/en
Application filed by 이종기, 제일제당 주식회사 filed Critical 이종기
Priority to CH00454/95A priority patent/CH687233A5/en
Priority to NL9420005A priority patent/NL194910C/en
Priority to DE4493997T priority patent/DE4493997T1/en
Priority to CA002141871A priority patent/CA2141871C/en
Priority to EP94917176A priority patent/EP0702564B1/en
Priority to DE4447677A priority patent/DE4447677C2/en
Priority to JP7501593A priority patent/JP2911603B2/en
Priority to GB9502373A priority patent/GB2285925B/en
Priority to AT0900694A priority patent/AT408445B/en
Priority to AU68571/94A priority patent/AU676575B2/en
Priority to RU95113158/13A priority patent/RU2155226C2/en
Priority to ES09550003A priority patent/ES2074968B1/en
Priority to CN94190491A priority patent/CN1112356A/en
Priority to DE4493997A priority patent/DE4493997C2/en
Priority to PCT/KR1994/000062 priority patent/WO1994028928A1/en
Priority to TW083105105A priority patent/TW403655B/en
Publication of KR950000164A publication Critical patent/KR950000164A/en
Priority to SE9500418A priority patent/SE507114C2/en
Priority to NO19950421A priority patent/NO317148B1/en
Priority to US08/773,330 priority patent/US5861163A/en
Publication of KR970001710B1 publication Critical patent/KR970001710B1/en
Application granted granted Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 약독화 녹농균의 세포벽 단백질 성분을 동물에게 접종하여 생성을 유도한 면역글로부린을 함유하는 녹농균 감염증 치료제 및 그의 제조방법에 관한 것이다. 본 발명에서 이용되는 약독화 녹농균주는 피셔 면역형태에 따른 7종의 녹농균주로 부터 약독화된 균주인 CFCPA 10142, CFCPA 20215, CFCPA 30720, CFCPA 40057, CFCPA 50243, CFCPA 60534 및 CFCPA 70018이며, 바람직하게는 CFCPA 10142, CFCPA 20215, CFCPA 30720 및 CFCPA 60534의 4종의 약독화 균주이다.The present invention relates to a therapeutic agent for Pseudomonas aeruginosa infections containing immunoglobulin induced by inoculation of animals with the cell wall protein component of attenuated Pseudomonas aeruginosa and a method of producing the same. The attenuated Pseudomonas aeruginosa used in the present invention is CFCPA 10142, CFCPA 20215, CFCPA 30720, CFCPA 40057, CFCPA 50243, CFCPA 60534 and CFCPA 70018, which are attenuated strains from seven Pseudomonas aeruginosa strains according to the Fischer immunoform. Four attenuated strains of CFCPA 10142, CFCPA 20215, CFCPA 30720 and CFCPA 60534.

본 발명에 따르는 면역글로부린 제제는 녹농균 감염증에 대해 우수한 치료효과 및 예방효과까지를 나타낸다.The immunoglobulin preparations according to the present invention exhibit excellent therapeutic and prophylactic effects against Pseudomonas aeruginosa infections.

Description

녹농균 감염증 치료제 및 그의 제조방법Pseudomonas aeruginosa infectious agent and its manufacturing method

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (10)

안전한 약독화 녹농균주로부터 분리, 정제된 세포벽 단백질에 의해 유도된 녹농균에 대한 면역글로부린을 유효성분으로함유함을 특징으로 하는 녹농균 감염증 치료제 조성물.A composition for treating Pseudomonas aeruginosa infections, comprising immunoglobulin against Pseudomonas aeruginosa isolated from a safe attenuated Pseudomonas aeruginosa strain as an active ingredient. 제1항에 있어서, 약독화 녹농균주가 녹농균의 피셔 면역형 1,2,3,4,5,6 및 7에 상응하는 균주임을 특징으로 하는 녹농균감염증 치료제.The agent for treating Pseudomonas aeruginosa infection according to claim 1, wherein the attenuated Pseudomonas aeruginosa strain is a strain corresponding to Fisher's immunotypes 1,2,3,4,5,6 and 7 of Pseudomonas aeruginosa. 제2항에 있어서, 약독화 녹농균주가 CFCPA 10142(KCCM 10029), CFCPA 20215(KCCM 10030), CFCPA 30720(KCCM 10031),CFCPA 40057(KCCM 10032), CFCPA 50243(KCCM 10033), CFCPA 60534(KCCM 10034) 및 CFCPA 70018(KCCM 10035)중에서 선택됨을 특징으로 하는 녹농균 감염증 치료제.The attenuated Pseudomonas aeruginosa strain according to claim 2, wherein CFCPA 10142 (KCCM 10029), CFCPA 20215 (KCCM 10030), CFCPA 30720 (KCCM 10031), CFCPA 40057 (KCCM 10032), CFCPA 50243 (KCCM 10033), CFCPA 60534 (KCCM 10034). ) And CFCPA 70018 (KCCM 10035). 제3항에 있어서, 약독화 녹농균주가 CFCPA 10142(KCCM 10029), CFCPA 20215(KCCM 10030), CFCPA 30720(KCCM 10031) 및CFCPA 60534(KCCM 10034)임을 특징으로 하는 녹농균 감염증 치료제.The agent of claim 3, wherein the attenuated Pseudomonas aeruginosa strains are CFCPA 10142 (KCCM 10029), CFCPA 20215 (KCCM 10030), CFCPA 30720 (KCCM 10031) and CFCPA 60534 (KCCM 10034). 제1항에 있어서, 약제학적으로 허용되는 담체와 함께 동결건조제제의 형태로 제형화된 녹농균 감염증 치료제.The agent for treating Pseudomonas aeruginosa infection according to claim 1, formulated in the form of a lyophilized preparation with a pharmaceutically acceptable carrier. 제5항에 있어서, 약제학적으로 허용되는 담체가 만니톨, 락토즈, 사카로즈 또는 인체 알부민임을 특징으로 하는 녹농균감염증 치료제.The agent for treating Pseudomonas aeruginosa infection according to claim 5, wherein the pharmaceutically acceptable carrier is mannitol, lactose, saccharose or human albumin. 제1항에 있어서, 약제학적으로 허용되는 담체와 함께 액체제제로 제형화된 녹농균 감염증 치료제.The agent for treating Pseudomonas aeruginosa infection according to claim 1, formulated in a liquid formulation together with a pharmaceutically acceptable carrier. 제7항에 있어서, 약제학적으로 허용되는 담체가 생리식염수, 주사용 증류수, 인산염 완충액 또는 수산화 알루미늄임을 특징으로 하는 녹농균 감염증 치료제.8. The agent for treating Pseudomonas aeruginosa infection according to claim 7, wherein the pharmaceutically acceptable carrier is physiological saline, distilled water for injection, phosphate buffer or aluminum hydroxide. 제1항에 있어서, 주사제, 정제, 캅셀제, 점안제, 분무제 또는 연고제의 형태로 제형화된 녹농균 감염증 치료제.The agent for treating Pseudomonas aeruginosa infection according to claim 1, formulated in the form of an injection, tablet, capsule, eye drop, spray or ointment. a)피셔 면역형태에 따라 순수하게 분리하여 반복적으로 순화시킴으로써 약독화시켜 수득한 약독화 녹농균주를 배양하여수득한 균체를 유기용매로 처리하여 미생물을 불활성화시키는 동시에 세포벽의 지질성분을 제거하고, b) 수득한 균체로부터 세포벽 단백질을 추출분리한 후. c) 수득된 세포벽 단백질을 한외여과하여 분자량이 10,000 내지 100,000범위인 단백질 성분만을 분리하고, d) 이 단백질 성분을 초원심분리시켜 세포벽 단백질만을 순수하게 분리시킨 다음, e) 분리된 세포벽 단백질을 동물에게 접종하고, f) 접종된 동물로부터 혈액을 채취하고, g) 채혈된 혈액으로부터 면역글로부린을 분리시켜 정제함을 특징으로 하여, 제1항 내지 9항중의 어느 하나에 따른 녹농균 감염증 치료제를 제조하는 방법.a) cultivate the attenuated Pseudomonas aeruginosa strain obtained by attenuating by repeatedly purifying and purifying purely according to Fisher's immune form, treating the obtained cells with an organic solvent to inactivate microorganisms, and at the same time removing lipid components from the cell wall, b ) After extracting the cell wall protein from the obtained cells. c) ultrafiltration of the obtained cell wall protein to separate only protein components having molecular weights ranging from 10,000 to 100,000, d) ultracentrifugation of this protein component to purely separate only cell wall proteins, and e) separating the cell wall proteins from animals. And f) collecting blood from the inoculated animal, g) isolating and purifying the immunoglobulin from the collected blood, thereby preparing a therapeutic agent for Pseudomonas aeruginosa infection according to any one of claims 1 to 9. Way. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930010281A 1993-06-07 1993-06-07 Pseudomonas infection preventing agent and the method of preparation thereof KR970001710B1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
KR1019930010281A KR970001710B1 (en) 1993-06-07 1993-06-07 Pseudomonas infection preventing agent and the method of preparation thereof
ES09550003A ES2074968B1 (en) 1993-06-07 1994-06-02 NEW STRAINED AERUGINOUS PSEUDOMONAS STRAINS.
NL9420005A NL194910C (en) 1993-06-07 1994-06-02 Weakened strain of Pseudomonas aeruginosa, as well as a vaccine and a drug against Pseudomonas aeruginosa infections, and a method of preparing the vaccine.
CA002141871A CA2141871C (en) 1993-06-07 1994-06-02 Novel attenuated pseudomonas aeruginosa strains
EP94917176A EP0702564B1 (en) 1993-06-07 1994-06-02 Novel attenuated pseudomonas aeruginosa strains
DE4447677A DE4447677C2 (en) 1993-06-07 1994-06-02 New attenuated Pseudomonas aeruginosa strains
JP7501593A JP2911603B2 (en) 1993-06-07 1994-06-02 A novel attenuated Pseudomonas aeruginosa strain
GB9502373A GB2285925B (en) 1993-06-07 1994-06-02 Novel attenuated pseudomonas aeruginosa strains
CN94190491A CN1112356A (en) 1993-06-07 1994-06-02 Novel attenuated pseudomonas aeruginosa strains
AU68571/94A AU676575B2 (en) 1993-06-07 1994-06-02 Novel attenuated pseudomonas aeruginosa strains
CH00454/95A CH687233A5 (en) 1993-06-07 1994-06-02 Novel attenuated Pseudomonas aeruginosa tribes.
DE4493997T DE4493997T1 (en) 1993-06-07 1994-06-02 New attenuated Pseudomonas Aeruginosa strains
AT0900694A AT408445B (en) 1993-06-07 1994-06-02 NEW ATTENUATED PSEUDOMONAS AERUGINOSA TRIBES
DE4493997A DE4493997C2 (en) 1993-06-07 1994-06-02 New attenuated Pseudomonas Aeruginosa strains
PCT/KR1994/000062 WO1994028928A1 (en) 1993-06-07 1994-06-02 Novel attenuated pseudomonas aeruginosa strains
RU95113158/13A RU2155226C2 (en) 1993-06-07 1994-06-02 New attenuated strain pseudomonas aeruginosa
TW083105105A TW403655B (en) 1993-06-07 1994-06-04 Novel attenuated pseudomonas aeruginosa strains
SE9500418A SE507114C2 (en) 1993-06-07 1995-02-06 New attenuated Pseudomonas aeruginosa strains
NO19950421A NO317148B1 (en) 1993-06-07 1995-02-06 New attenuated Pseudomonas aeruginosa strains, vaccines, method of preparation thereof and therapeutic agent
US08/773,330 US5861163A (en) 1993-06-07 1996-12-24 Process for preparing a vaccine against pseudomonas aeruginosa using attenuated strains

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019930010281A KR970001710B1 (en) 1993-06-07 1993-06-07 Pseudomonas infection preventing agent and the method of preparation thereof

Publications (2)

Publication Number Publication Date
KR950000164A true KR950000164A (en) 1995-01-03
KR970001710B1 KR970001710B1 (en) 1997-02-14

Family

ID=19356971

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930010281A KR970001710B1 (en) 1993-06-07 1993-06-07 Pseudomonas infection preventing agent and the method of preparation thereof

Country Status (1)

Country Link
KR (1) KR970001710B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102561568B1 (en) * 2016-03-03 2023-08-01 아이진 주식회사 Attenuated Pseudomonas aeruginosa Having Improved Productivity and Safety, and Vaccine Composition Comprising the Same

Also Published As

Publication number Publication date
KR970001710B1 (en) 1997-02-14

Similar Documents

Publication Publication Date Title
EP0556241B1 (en) Mycobacterium vaccae in the treatment of uveitis
Burnett et al. The chemistry and toxicology of some venomous pelagic coelenterates
CLAYTON et al. Membrane fractions of trypanosomes mimic the immunosuppressive and mitogenic effects of living parasites on the host
Kong et al. Immunogenic properties of nondisrupted and disrupted spherules of Coccidioides immitis in mice
EP0153969B1 (en) Transfer factor composition for skin treatment
US4203971A (en) Neisseria gonorrhoeae vaccine
AU683835B2 (en) Therapeutic agent from mycobacterium vaccae and its use against HIV infection
EP0484438B1 (en) Biological preparation and its use
EP0252064B1 (en) Preparations active against pseudomonas aeruginosa infections, and process for their preparation
WO2002092131A3 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
Seed Trypanosoma gambiense and T. equiperdum: Characterization of variant specific antigens
JP2911603B2 (en) A novel attenuated Pseudomonas aeruginosa strain
KR950000164A (en) Pseudomonas aeruginosa infectious agent and its manufacturing method
Jones Protection against Pseudomonas aeruginosa infection by immunisation with fractions of culture filtrates of Ps. aeruginosa.
RU95113158A (en) NEW IMPAIRED PSEUDOMONAS AERUGINOSA STRAINS
Shiota et al. Pneumocystis carinii infection in corticosteroid-treated cats
Siebert Jr et al. Taenia crassiceps: effect of normal and immune serum on metacestodes in vitro
EP0003529A1 (en) Antigens from Trypanosoma cruzi, purification thereof, and their use in vaccines
KR950000158A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 20215 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections
Hurwitz Erythema chronicum migrans and Lyme disease
KR950000159A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 30720 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections
KR950000163A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 70018 for the manufacture of a therapeutic and preventive vaccine for Pseudomonas aeruginosa infections
KR950000157A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 10142 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections
D'ANTONIO et al. Model system for study of artificially induced resistance to malaria
KR950000161A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 50243 for the manufacture of a therapeutic and preventive vaccine for Pseudomonas aeruginosa infections

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080626

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee